← boardnext 2026-12next 2027-09
TRVI
TR Therapeuticsdistress 1/10 · well-funded / low risk$17.26-1%today-11% from 52w high
Respiratory 2
Lead: IPF-related chronic cough
Revenue
pre-revenue
Liquidity
$173M
Runway
3.8 yrs
Shares 1y
+17%
Price & events
+57.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.6%
1D
-0.6%
1W
-0.7%
1M
+21.6%
3M
+72.8%
6M
+118.8%
1Y
+483.1%
2Y
+771.7%
5Y
+551.3%
All
Overview
- Market Cap
- $2.45B
- Volume
- 97.81K
- 52 Week Range
- $6.55 – $19.50
- Total Shares
- 141.98M
- Float Shares
- 118.77M
- Short %
- 10.85%
- % Held by Insiders
- 0.63%
- % Held by Institutions
- 99.29%
- RVOL
- 0.03x
- Beta
- 1.00
Pipeline stages · 2 programs
TR987 0.1% gel
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
NAL ER
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 9 trials · 4 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12 Estimated 50% readout ~2027-02-14 | Phase 3 | TR987 0.1% gel | Venous Leg Ulcer, Venous Ulcer, Venous Stasis Ulcer, Venous Stasis, Wound Heal, Wound, Venous Insufficiency of Leg, Non-healing Wound | — | recruiting |
| 2027-09 Estimated 50% readout ~2027-10-16 | Phase 2 | NAL ER | Refractory Chronic Cough | — | not yet recruiting |
| 2027-12 Estimated 50% readout ~2028-02-14 | Phase 3 | TR987 0.1% gel | Venous Leg Ulcer, Venous Ulcer, Venous Stasis Ulcer, Venous Stasis, Wound Heal, Wounds, Venous Insufficiency of Leg, Non-healing Wound | — | recruiting |
| 2028-06 Estimated 50% readout ~2028-08-15 | Phase 3 | NAL ER | Idiopathic Pulmonary Fibrosis | — | not yet recruiting |
| 2026-06-30 | Phase 1 | NAL ER, Placebo | Idiopathic Pulmonary Fibrosis | 10 | recruiting |
Show all 9 trials · 4 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-04 | Phase 1 | NAL ER | Healthy Participants | 60 | recruiting |
| 2025-09-12 | Phase 1 | NAL ER, Pirfenidone, Nintedanib | Healthy Participants | 132 | completed |
| 2025-04-24 | Phase 2 | NAL ER, Placebo, NAL ER, NAL ER | Idiopathic Pulmonary Fibrosis | 165 | completed |
| 2025-01-06 | Phase 2 | NAL ER, Placebo | Refractory Chronic Cough | 66 | completed |
Catalyst news & presentations · 15
- first half of 2028Guided 55%readoutPhase 3Haduvio · Topline results from first Phase 3 trialSEC 8-K
- second half of 2027Guided 55%readoutPhase 2Haduvio · Topline results from Phase 2b trialSEC 8-K
- second half of 2026Guided 55%trial initiationsecondaryPhase 2Haduvio · Phase 2b trial for non-IPF ILD chronic coughSEC 8-K
- second half of 2026Guided 55%trial initiationsecondaryPhase 3nalbuphine ER · Second pivotal Phase 3 trial, 130 patients, 12 weeks fixed dosing.SEC 8-K
- fourth quarter of 2026Guided 70%readoutPhase 2Haduvio · Sample size re-estimation analysis for RCC Phase 2bSEC 8-K
- 2026-08-06earningsEarningsEarnings releaseyahoo
- second quarter of 2026trial initiationsecondaryPhase 2Haduvio · Phase 2b trial for RCCSEC 8-K
- second quarter of 2026trial initiationsecondaryPhase 3nalbuphine ER · First pivotal Phase 3 trial, 300 patients, 52 weeks fixed dosing, primary endpoint at 24 weeks.SEC 8-K
- 2026-03-09fda agreementnalbuphine ER · FDA alignment on Phase 3 program design and Phase 1 supporting studies for NDA submission for IPF-related chronic cough.SEC 8-K
- second half of 2025trial initiationsecondaryHaduvio · Initiate clinical trial for non-IPF ILDSEC 8-K
- second half of 2025regulatory submissionFiled (NDA/BLA)Haduvio · Request end of Phase 2 meeting with FDASEC 8-K
- first half of 2025readoutPhase 2Haduvio · Topline results for CORAL trialSEC 8-K
- first quarter of 2025readoutPhase 2Haduvio · Topline results for RIVER trialSEC 8-K
- December 2024readoutPhase 2Haduvio · SSRE result for Phase 2b CORAL trialSEC 8-K
- 2024-10-21enrollment completesecondaryPhase 2Haduvio · Enrollment completed in Phase 2a RIVER trialSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $25 (+44% upside) · 10 analysts
- 2026-07-21BMO CapitalOutperform
- 2026-07-20HC Wainwright & Co.Buy
- 2026-07-20B. Riley SecuritiesBuy
- 2026-05-20NeedhamBuy
- 2026-05-06HC Wainwright & Co.Buy
- 2026-05-06NeedhamBuy
Competitors — IPF-related chronic cough
- none identified
Recent news
- 2026-07-22Trevi Therapeutics (NASDAQ:TRVI) Rating Increased to Strong-Buy at BMO Capital Markets - MarketBeat
- 2026-07-21TRVI Initiated Coverage by BMO Capital -- Rating Set to Outperfo - GuruFocus
- 2026-07-21BMO Capital Initiates Trevi Therapeutics at Outperform With $36 Price Target - marketscreener.com
- 2026-07-20Trevi Therapeutics (NASDAQ:TRVI) Shares Down 5.1% - Here's Why - MarketBeat
- 2026-07-20TRVI Maintains Buy by B. Riley Securities -- Price Target Raised to $31.00 - GuruFocus
- 2026-07-20TRVI Maintains Buy by B. Riley Securities -- Price Target Raised to $31.00 - GuruFocus
- 2026-07-20B. Riley Financial Issues Positive Forecast for Trevi Therapeutics (NASDAQ:TRVI) Stock Price - MarketBeat
- 2026-07-20TRVI Maintains Buy Rating -- Price Target Raised to $24.00 by HC Wainwright - GuruFocus
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.